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Retrospective study of concussive convulsions in elite
Australian rules and rugby league footballers:
phenomenology, aetiology, and outcome
Paul R McCrory, Peter F Bladin, Samuel F Berkovic
Abstract
Objectives: To study the ictal phenomenology,
aetiology, and outcome of convulsions occurring
within seconds of impact in violent collision sport.
Design: Retrospective identification of convulsions
associated with concussive brain injury from case
records from medical officers of football clubs over a
15 year period.
Subjects: Elite Australian rules and rugby league
footballers.
Main outcome measures: Neuroimaging studies,
electroencephalography, neuropsychological test data,
and statistics on performance in matches to
determine presence of structural or functional brain
injury. Clinical follow up and electroencephalography
for evidence of epilepsy.
Results: Twenty two cases of concussive convulsions
were identified with four events documented on
television videotape. Convulsions began within 2
seconds of impact and comprised an initial period of
tonic stiffening followed by myoclonic jerks of all
limbs lasting up to 150 seconds. Some asymmetry in
the convulsive manifestations was common, and
recovery of consciousness was rapid. No structural or
permanent brain injury was present on clinical
assessment, neuropsychological testing, or
neuroimaging studies. All players returned to elite
competition within two weeks of the incident. Epilepsy
did not develop in any player over a mean (range)
follow up of 3.5 (1›13) years.
Conclusions: These concussive or impact convulsions
are probably a non›epileptic phenomenon, somewhat
akin to convulsive syncope. The mechanism may be a
transient traumatic functional decerebration. In
concussive convulsions the outcome is universally
good, antiepileptic treatment is not indicated, and
prolonged absence from sport is unwarranted.
Introduction
Convulsions that occur within seconds of impact are
an infrequent accompaniment of traumatic brain
injury. Their occurrence in collision sports such as
football and rugby creates public drama and manage›
ment challenges for the treating clinicians.
It has been widely assumed that these events repre›
sent a form of post›traumatic epileptic seizure (“impact
seizure”), secondary to underlying brain injury, with
all the medical and psychosocial consequences of
epilepsy.1 2 Large epidemiological studies of post›
traumatic epilepsy describe early (within one week)
and late (after one week) seizures after traumatic brain
injury.1›3 Both types of seizures have been shown to
have an epileptic basis. In contrast, convulsions within
seconds of head injury have not been well studied and
certainly have not emerged as a risk factor for
post›traumatic epilepsy in studies of severe head
injury.4 We studied these concussive convulsions in
Australian footballers to determine if there was
evidence that these were epileptic in origin and if they
were associated with lasting brain injury. These
findings have implications for management of patients
and, in the case of professional sportsmen, major
implications for career and lifestyle.
Methods
We retrospectively identified convulsions associated
with concussive brain injury from case records of all
club medical officers in elite Australian rules football
competition over a 15 year period. The league is a
national football competition, and in the 15 year
period about 200 000 player games occurred. Twenty
episodes of concussive convulsions were identified, and
all cases were followed up. This probably represents
total ascertainment of cases because of the dramatic
nature of the episodes concerned. We also included
two additional cases of concussive convulsions that
occurred in elite rugby league during the time frame of
the study.
In all 22 cases eyewitness accounts of the episodes
were obtained from medical officers. In four of the 22
cases, television videotape of sufficient quality was
available for detailed analysis of the event. These cases
allowed the detailed ictal phenomenology of the
convulsive episodes to be determined.
The routine management after concussion in
Australian rules football entails clinical and brief
neuropsychological assessment. This assessment
includes questions of memory, orientation, digit
symbol substitution test (from the Wechsler adult intel›
ligence scale), and choice reaction time. These
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measures have been found to be sensitive markers
of mild traumatic brain injury in football.5›7 The
concussed player’s results are then compared with his
preseason baseline assessment. Seventeen players were
followed up in the period after injury by serial clinical
and neuropsychological testing.
Functional measures of performance from match
statistics were recorded before and after injury. These
were available for all 22 Australian football cases. The
mean number of ball possessions per quarter was cal›
culated over four games before and after injury. Match
statistics from an equal number of randomly selected
controls matched for age were used for comparison.
The control data were derived from a prospective data›
base of football statistics recorded for ongoing
research in head injury related to football.6 8 9
All players in the study were followed up clinically.
In all cases, neuroimaging data and the original
electroencephalographic records were sought from
the treating neurologists and neurosurgeons.
Results
The 22 identified episodes occurred in footballers aged
19›30 years (mean 23.4 years).
Case report—A 24 year old footballer was struck on
the left side of the face by an opponent’s elbow during
a collision (fig 1 (left)). As he fell towards the ground
loss of consciousness was apparent, and he developed
tonic arm posturing with both clenched fists in a “bear
hug” position (fig 1 (centre)). His legs were extended
and his head and eyes were turned to the right. After
20 seconds of tonic posturing, a series of generalised
symmetrical myoclonic jerks occurred for 30 seconds
(fig 1 (right)). His loss of consciousness was 2 minutes,
and he had 45 minutes of post›traumatic amnesia.
Results of subsequent neurological examination,
electroencephalography, and cerebral magnetic reso›
nance imaging studies were normal. He returned to
football the following week without further effects and
has continued his football career for a further six years
without problem.
Ictal phenomenology
Table 1 shows separate analyses of all 22 eyewitness
accounts and of the four videotaped cases. Typically,
after a violent collision the player lost consciousness
and started convulsive movements within 2 seconds of
impact. The mean (range) time to onset in the video
cases was 0.75 seconds (range 0›2.0 seconds). The con›
vulsion usually entailed a brief tonic phase followed by
bilateral myoclonic jerking. Asymmetrical posturing
and versive head movements were seen in all video
cases but recalled less often (31%) by the eyewitness
accounts. The episodes ceased spontaneously within
150 seconds, and the players woke with behavioural
and neuropsychological features indistinguishable
from mild concussion.
Of particular interest were two footballers who
were alert and orientated within seconds of the termi›
nation of the convulsive event. Both cases were
documented on videotape. The first of these was an
Australian rules footballer whose convulsive event
lasted 150 seconds; he then woke up on the stretcher as
he was being carried off the ground. The second was a
rugby league player in an international test match who
sustained an event in the opening minute of the game.
After recovery he returned to the field and performed
sufficiently well to be voted “man of the match.” In
both cases, clinical and neuropsychological assessment
after injury yielded normal results, and both players
returned to sport the following week without problem.
The mechanism of injury, as determined by the site
of impact, was a direct facial blow in all four videotaped
cases. Eyewitness reports in the 18 other cases
suggested that around half were facial blows, a quarter
were occipital, and the remainder were uncertain.
Investigations
All players had either computed tomographic (10
cases) or magnetic resonance (12 cases) brain imaging,
which yielded normal results. Twenty one players
Fig 1 This football player was accidentally struck in jaw at high speed resulting in
immediate unconsciousness (left). As he fell towards the ground 0.7 seconds after impact
he was convulsing with arms extended in tonic “bear hug” position (centre). Bilateral
myoclonic twitching of limbs developed within 20 seconds of impact (right) and lasted for
further 30 seconds, when it ceased spontaneously
Table 1 Details of convulsive phenomenology in football players
Clinical features Eyewitness (n=22) Videoanalysis (n=4)
Mean (range) onset latency (sec) Immediate in all 0.75 (0›2)
Mean (range) duration (sec) 40 (10›120) 78 (30›150)
No (%) with:
Initial tonic posturing 6 (26) 3 (75)
Myoclonic jerks 20 (90) 4 (100)
Bilateral involvement 17 (79) 4 (100)
Lateralising features 7 (31) 4 (100)
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underwent electroencephalography after injury, which
yielded normal results with the exception of one, who
demonstrated transient left temporal slowing in the
immediate period after injury. Follow up electroen›
cephalograms performed at one week and 24 months
on that player have had normal results.
Outcome
The outcome for players with these events was univer›
sally good. All players returned to participation in elite
sport within two weeks of the episode without effects.
Results of serial neuropsychological tests performed
on 17 Australian football players returned to baseline
level within five days after injury (table 2). This is the
typical pattern after concussive brain injury seen in this
sport.5 6 Match statistics did not reveal any significant
difference in the match performance of injured players
before and after injury (table 3). Post›hoc analysis of
individual players’ performance did not show any
significant deterioration that might have been con›
cealed in the group statistics.
The mean (range) length of follow up was 3.5 (2 to
13) years. No player has gone on to develop epilepsy,
and seven of the 21 players have had further
concussive episodes without convulsions.
If we assume complete ascertainment of concussive
convulsions, these occurred 1 per 10 000 (20 out of
200 000) player games in elite Australian rules football.
Concussion is known to occur at a rate of 1 per 10
player games,8 10 so concussive convulsions occur once
in every 1000 concussions in this sport.
Discussion
Concussive convulsions described here in violent colli›
sion sport are an uncommon but dramatic association
with minor head injury that have been recognised
since the time of Gowers.11 12 Our video study showed
that these concussive convulsions occurred within 2 s
of impact. Moreover, they were not associated with
structural brain injury or with ongoing epilepsy or epi›
leptiform electroencephalographic abnormalities and
had a universally good outcome. Thus they are unlikely
to be epileptic in nature, and other pathophysiological
mechanisms need to be explored.
From a phenomenological standpoint, concussive
convulsions have more in common with convulsive
syncope than with post›traumatic epilepsy. Convulsive
syncope is a non›epileptic phenomenon thought
to reflect a loss of cortical inhibition coupled with
reflex brainstem activation.13 14 Clinical and video›
electroencephalographic analyses have demonstrated
a spectrum of convulsive movements ranging from
focal myoclonic jerks in mild cases to generalised
tonic›clonic events that resemble true epileptic
seizures.14›21 In many cases, lateralising features are
prominent. The episodes are usually brief, typically
lasting for only a few seconds, and occur after a delay
of less than 10 seconds. Unlike convulsive syncope,
concussive convulsions can last up to 150 seconds and
start with a latency of 2.0 seconds or less, making a
reflex cerebral ischaemic basis unlikely. Another
hypothesis, and the one we favour, is that the concus›
sive impact itself creates a transient functional
decerebration akin to the corticomedullary dissocia›
tion described above.
In the players suffering concussive convulsions, the
universally good outcome and absence of structural
injury or long term neuropsychological damage
reflects the benign nature of these episodes. From a
management standpoint, late seizures do not occur,
antiepileptic treatment is not indicated, and prohibi›
tion from collision sport is unwarranted. If an episode
follows the profile outlined above the treating clinician
can reassure the patient that concussive convulsions
are benign, and overall management should centre on
the appropriate treatment of the concussive injury
itself.
We thank Channel 7 Melbourne for provision of TV
videotape; the members of the Australian Football League
Medical Officers Association; Drs David Maddocks, John B
Table 2 Neuropsychological performance in footballers after concussive convulsions. Figures are means (95% confidence intervals)
Neuropsychological measure
Control players at
baseline* (n=20)
Concussed players (n=17 )
Baseline* Immediately after injury† 5 Days after injury
Digit symbol substitution test 65 (62 to 68) 66 (63 to 70) 40 (36 to 45)‡ 67 (66 to 70)
Choice reaction time:
Decision time (ms) 468 (448 to 488) 472 (454 to 490) 487 (471 to 503)‡ 460 (443 to 477)
Movement time (ms) 133 (119 to 148) 136 (124 to 165) 154 (143 to 165)‡ 133 (119 to 147)
*Test results from before season.
†Within 60 minutes after injury.
‡No significant difference with Student’s t test in comparison of baseline results between controls and concussed subjects or between baseline and late results in
concussed players. Significant (P<0.05) difference between baseline results and results immediately after injury in concussed players for all three neuropsychological
measures.
Table 3 Functional performance of footballers after concussive
convulsions according to match statistics. Figures are mean
number of possessions of ball per quarter (95% confidence
intervals)
Detail Before injury After injury P value*
Injured players (n=20) 5.2 (4.5 to 5.9) 5.5 (4.8 to 6.3) 0.09
Control players (n=20) 5.0 (4.7 to 5.3) 5.5 (5.0 to 6.0) 0.06
*Student’s t test.
Key messages
+ Concussive or impact convulsions are a
non›epileptic phenomenon
+ They are not associated with structural brain
injury
+ Antiepileptic treatment is not indicated
+ In the case of sporting injury, prolonged
absence from sport is unwarranted
+ Treatment entails the appropriate management
of the associated concussive injury
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Popularity of less frequent follow up for breast cancer in
randomised study: initial findings from the hotline study
Tim Gulliford, Magi Opomu, Elena Wilson, Iain Hanham, Richard Epstein
Abstract
Objective: To compare the experiences of patients
with breast cancer who were conventionally
monitored with those in whom routine follow up was
restricted to the time of mammography.
Design: Randomisation to conventional schedule of
clinic visits or to visits only after mammography. Both
cohorts received identical mammography and were
invited to telephone for immediate appointments if
they detected symptoms.
Setting: Combined breast clinic, Chelsea and
Westminster Hospital.
Subjects: 211 eligible outpatients with a history of
breast cancer.
Main outcome measures: Acceptability of
randomisation, interim use of telephone and general
practitioner, satisfaction with allocation to follow up.
Results: Of 211 eligible patients, 196 (93%) opted for
randomisation in the study. Of these, 55 were under
50 years, 78 were diagnosed fewer than five years
before, 90 had stage T2›4 tumours, and 71 had
involved axillary nodes. Patients who did not
participate were more likely to be under 50 years, to
be two to five years after diagnosis, and to have had
aggressive primary disease. Twice as many patients in
both groups expressed a preference for reducing
rather than increasing follow up. No increased use of
local practitioner services or telephone triage was
apparent in the cohort randomised to less frequent
follow up by specialists.
Conclusions: Reducing the frequency of routine
follow up has so far proved popular among patients
with breast cancer at standard risk in this cohort. A
multicentre study is needed to determine the
effectiveness and cost›effectiveness of routine follow
up with respect to disease outcomes.
Introduction
Most patients who relapse after treatment for primary
breast cancer do so within the first five years of follow
up.1 As curable intramammary relapses are more
sensitively detected by mammography than by clinical
examination,2 regular mammography after lumpec›
tomy has now become accepted practice in most
centres. Asymptomatic detection of disseminated
disease is also achievable by using routine radiological
or serologic testing, or both, but objective benefit from
this approach has not been shown. Indeed, the only
undisputed effect of intensive monitoring is that of
diminished relapse free survival.3 It is therefore not
surprising that many retrospective studies have cast
doubts on the effectiveness of routine non›
mammographic investigations or clinical follow up, or
both, for breast cancer.4›7 Despite these doubts routine
follow up continues to be the norm, with many physi›
cians assuming that patients are reassured by frequent
contact with their oncologist.8 This view is not
universal, however, as evidenced by wide disparities in
follow up practice on both sides of the Atlantic9›11; dis›
parities that have been attributed to defensive percep›
tions by physicians unsure as to the efficacy of
treatment and monitoring.12 13 For these reasons many
authorities have lately acknowledged the need for a
prospective randomised study to determine the
benefits of the tradition of routine follow up.14›17
In this pilot study we compared the experience
of a cohort who received conventional follow up
with that of a similar cohort in whom review, in the
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absence of symptoms, was restricted to the time of
mammography.
Patients and methods
Participants—All eligible patients seen at the
Chelsea and Westminster combined breast clinic over a
24 month period were offered randomisation. Eligibil›
ity criteria were a history of breast cancer proved by
biopsy; lack of known recurrence of cancer; current
lack of symptoms consistent with recurrence; no active
management apart from adjuvant tamoxifen; home
telephone; fluency in English; and informed consent.
Details of disease stage for patients who declined par›
ticipation were recorded anonymously to provide an
internal control for recruitment bias. Primary treat›
ment and staging details were obtained from
information in medical records, the Charing Cross
CTS computer system, correspondence with patients,
and archives. Median follow up for the present analysis
was 16 months.
Follow up and mammography scheduling—Table 1
presents the schedule for visits. No restrictions were
placed on attendance at other hospital or local clinics.
Patients older than 70 years and for whom over five
years had passed since diagnosis were not routinely
scheduled for mammography but continued outpa›
tient review according to the same schedule shown in
table 1. All patients were advised to examine their
breasts each month and to request an immediate
appointment if they felt a lump or developed any other
symptom.
Telephone access and questionnaires—All patients were
instructed to telephone immediately if they developed
symptoms or had other concerns; in these circum›
stances an appointment to be seen within five working
days was made. Records were kept concerning the
content of all telephone calls from patients in the study.
Questionnaires based on the Medical Research Coun›
cil quality of life questionnaire were used and included
additional questions relating to frequency of follow up
in hospital and general practice, satisfaction with clinic
visits, and the time and expense entailed in clinic
attendance; these were sent to patients annually, begin›
ning six months after study entry.
Protocol violation and termination—Documentation
of progression of disease or second malignancy
automatically terminated participation in the study (10
patients) as did any decision after randomisation by
any patient to pursue an alternative schedule of
appointments or mammograms to that specified in the
protocol (three patients).
Table 1 Scheduling of clinic visits
Interval since
diagnosis (years) Conventional
Mammogram only
Lumpectomy Mastectomy
<1 3 months 1 year 1 year
1›2 4 months 1 year 2 years
2›5 6 months 1 year 2 years
>5 1 year 2 years 2 years
Table 2 Characteristics of patients in each randomisation group.
Figures are numbers (percentages) of patients
Conventional Mammogram only
Age at diagnosis (years):
No of subjects* 96 97
≤49 27 (28) 29 (30)
50›65 47 (49) 49 (51)
>65 22 (23) 19 (20)
Surgery:
No of subjects* 85 90
Lumpectomy 61 (72) 58 (64)
Mastectomy 24 (28) 32 (36)
Adjuvant treatments:
Irradiation after lumpectomy 56 (89) 52 (84)
Tamoxifen 67 (50) 72 (57)
Tumour stage:
No of subjects* 63 64
T1 (≤2 cm) 36 (57) 33 (52)
T2 (>2 cm) 22 (35) 26 (40)
T3/4 5 (8) 5 (8)
Nodal stage:
No of subjects* 74 82
Nx 24 (32) 28 (34)
N0 34 (46) 33 (40)
N1 16 (22) 21 (26)
Years since diagnosis:
No of subjects* 95 96
<2 18 (19) 18 (19)
2›5 17 (18) 23 (24)
>5 60 (63) 55 (57)
*Numbers of subjects differ because of inability to confirm precise
information—for example, date of diagnosis, date of birth, etc.
Table 3 Characteristics of non›participants. Figures represent
the frequency of indicated clinical feature in non›participants
expressed as percentage of that feature in total population of
eligible patients
Non›participants (15/211; 7.1%)
Age at diagnosis (years):
≤49 9.7% (6/62)
50›65 6.8% (7/103)
>65 4.7% (2/43)
Tumour stage:
T1 (≤2 cm) 5.5% (4/73)
T2 (>2 cm) 9.4% (5/53)
T3/4 16.7% (2/12)
Nodal stage:
Nx 8.8% (5/57)
N0 5.6% (4/71)
N1 14.0% (6/43)
Years since diagnosis at entry to study:
<2 7.8% (3/39)
2›5 14.9% (7/47)
>5 4.2% (5/120)
Table 4 Events between scheduled appointments: telephone
calls and visits to general practitioners
Interim events Conventional Mammogram only
Telephone calls:
Blood test/x ray results 0 2
Tamoxifen query 0 2
Questionnaire query 2 2
Mammogram appointment 1 1
Clinic appointment 8 1
Visits to general practitioner:
Cancer related 7 4
Not cancer related 39 49
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Results
Patterns of patient recruitment—Age distribution,
duration since diagnosis, and primary disease stage did
not differ substantially between the cohorts (table 2).
Fifteen eligible patients (7%) declined participation;
this group was distinguished by a trend towards a
higher stage of primary disease, younger age, and
more recent diagnosis; other parameters were not
appreciably different (table 3). We consider that the
minor degree of selection bias suggested here does not
confound the broad conclusions of this study.
Interval events
Telephone calls and visits to general practitioners—
Twenty one telephone calls from patients without
symptoms were received during this phase of the
study: 11 in the conventional arm and eight in the
mammogram only arm. Of note, eight of the 11 calls in
the conventional arm related to queries about clinic
appointments compared with only one such query in
the mammogram only arm (table 4). Hence, the poten›
tial problems of a heavy workload of telephone
counselling in the mammogram only cohort have so
far failed to materialise, consistent with the experience
of other clinical groups who have successfully used tel›
ephone advice lines.18 Forty six visits to general practi›
tioners were recorded in the conventional cohort
compared with 53 in the mammogram only group.
Seven (15%) visits in the former group, however, were
related to cancer problems compared with only four
(7.5%) in the latter (table 4). Although these numbers
are small, this finding suggests that less frequent
specialist follow up of patients without symptoms may
not necessarily translate into a heavier burden of care
for local practitioners.
Response to clinic visits—A similar majority of
respondents in both cohorts thought that their clinic
visit was reassuring, perhaps more so than similar fol›
low up with their general practitioner alone (table 5).
This is consistent with the findings of similar
studies,19 20 though some have suggested community
follow up to be equally popular.21 Similar proportions
of patients in both arms admitted a preference for
either more or less frequent follow up visits, though in
absolute terms more than twice as many favoured the
latter (table 5).
Time and expense entailed in clinic visits—With respect
to the inconvenience of attending the clinic as assessed
by questionnaire, no substantial differences were
apparent between the two groups. A minimum of four
hours from door to door was required for clinic
attendance in 73 patients (median three hours); 37
needed to take time off work and 80 were accompanied
by another person (a quarter of whom needed to take
time off work). No personal costs in attending clinics
were incurred by 67, while 49 of the remainder
incurred costs in excess of £10 and eight more than
£50.
Discussion
The present study is limited by its size and duration
and does not justify publication of immature data con›
cerning recurrence and quality of life. A study of
survival outcomes would require several thousand
patients and many years of follow up to establish the
relative incidence of uncontrolled local recurrence,
particularly late stage recurrence within the breast. The
early phase of such a study would also need to focus on
the possibility of more local or distant recurrences, or
both, being detected in the “conventional” group, thus
implying a shorter lead time (and, perhaps, more effec›
tive local treatment). Interim analysis of the present
results indicates that no such trend has yet emerged;
indeed, of the recurrences documented to date, all have
been detected at interval (as opposed to scheduled)
visits. We acknowledge, however, that these unpub›
lished observations fall short of establishing the safety
of less frequent follow up.
What does seem clear from the present study is that
this cohort of patients with breast cancer was highly
supportive of the option to pursue less frequent follow
up and seemed willing to assume responsibility for
seeking medical attention in the event of symptoms.
These findings are consistent with those of other
groups.22 Moreover, the data reveal surprisingly little
hesitancy from subgroups one might have expected to
be reluctant—that is, the young, the recently diagnosed,
and those with more aggressive primary disease—
notwithstanding that this profile was somewhat
over›represented among the patients who did not par›
ticipate.
The potential benefits of less intensive monitoring
are clear. Clinicians are able to rationalise their
practices and thus improve the efficiency of patient
care; anxiety and inconvenience for patients without
symptoms is minimised; outpatient clinic waiting time
Table 5 Patients’ responses to clinic visits and desired future frequency. Figures are numbers (percentages) of patients
Feeling about clinic visits Conventional Mammogram only
Psychological effect:
Reassuring 73 (94) 69 (88)
Wish to continue with hospital based follow up rather than with general practitioner alone 74 (94) 70 (89)
Future visit schedule:
Prefer more frequent 7 (11) 10 (16)
Prefer less frequent 17 (25) 22 (35)
Table 6 Response of funding agencies to requests for study support
Funding body approached Application verdict
NHS Worthy study, but more appropriately funded by local audit fund
Local audit fund Worthy study, but more appropriately funded by extramural Research Funding Body
Extramural Research Funding Body Worthy study, but more appropriately funded by NHS
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is reduced, increasing evaluation time for sick patients;
nursing and reception staff are able to provide higher
quality outpatient service by having fewer arrivals and
room changes to deal with; the efficiency of general
practitioner referral to hospital specialists improves;
and healthcare purchasers reap the rewards of greater
cost›effectiveness. Given this potentially attractive
harvest, financial support for this pilot study was been
surprisingly hard to find (table 6). None the less, we
submit that these preliminary findings establish both
the feasibility and desirability of a larger and more
comprehensive national initiative to establish the value
of routine follow up for cancer and other diseases.
We thank E Woods for assistance with randomisation, C
Coombes for support, and our patients for their kind and spir›
ited cooperation.
Funding: TG is supported by the Medical Research Council
and RE by the Cancer Research Campaign.
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Opening my mind
I was a young consultant gynaecologist in 1975 when I saw a 25 year
old woman with large venereal warts. I advised ablating them with
cryocautery, but she was not happy with this advice, as she wanted to
avoid surgery as far as possible. She went away and when she came
back after six weeks I found to my surprise that the warts had
disappeared. I asked her if she had had the surgery done elsewhere,
but she told me that they had “melted away” after she had taken a
homoeopathic medicine called Thuja.
This was my first introduction to homoeopathy and I was
impressed by how well it had worked for her. As a doctor trained in
Western medicine I was sceptical about alternative medicine, but I
kept an open mind and bought all the textbooks on homoeopathy
that I could find to learn more about this system of treatment. Since
these were written many years ago, they used quaint language and
archaic medical terms which I found quite amusing and hard to
decipher as well. I also had to start thinking of doses in terms of
potency rather than in terms of milligrams.
I suspended my initial disbelief and decided to try homoeopathy.
Much to my surprise, it often worked, and this was a valuable learning
experience for me. I may not subscribe to the “small is better”
philosophy of homoeopathy, and neither do I pretend to understand
why it works. But the fact that it sometimes does in indisputable. As a
clinician I am happy to use whatever works for my patients, and the
system of medicine that I use is unimportant. Historically, especially in
the West, there has been a conflict between allopathic medicine and
other systems but this was a political struggle for the “power to
practise medicine.” Today, we should look for a balanced middle
ground.
I agree that we need to be sceptical, especially when
unsubstantiated claims are made for alternative medicine’s ability to
cure all ills from AIDS to cancer. But there is the danger of throwing
out the baby with the bathwater, and we must learn to keep an open
mind. This will allow us to serve our patients better. I still use
homoeopathy, especially when Western medicine does not have a
better alternative to offer. Thanks to this experience I am now able to
offer my patients treatment which works for them—“integrated
medicine”—and the best of all possible worlds.
Chandrakala Malpani is a consultant gynaecologist in Bombay
We welcome filler articles of up to 600 words on topics such as A
memorable patient, A paper that changed my practice, My most unfortunate
mistake, or any other piece conveying instruction, pathos, or humour.
If possible the article should be supplied on a disk.
Key messages
x Although it is standard practice to advocate
routine long term follow up of patients with
breast cancer, the effectiveness of
non›mammographic follow up has not been
assessed in randomised trials
x A key concern that has delayed the
implementation of such trials is whether
patients would find symptom driven follow up
psychologically acceptable
x In this study most patients agreed to undergo
randomisation to less frequent follow up,
though all continued with routine
mammographic review
x After randomisation more patients expressed a
desire to reduce further, rather than increase,
the frequency of follow up
x Patients undergoing less frequent review did not
increase their use of general practitioner or
telephone (hotline) services
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Weight loss in people with Alzheimer’s disease: a
prospective population based analysis
Diane Cronin›Stubbs, Laurel A Beckett, Paul A Scherr, Terry S Field,
Marilyn J Chown, David M Pilgrim, David A Bennett, Denis A Evans
Weight loss among older people, often due to
conditions such as cancer and heart disease, has been
associated with increased risks of disability and
mortality.1 Alzheimer’s disease may be a more
important source of weight loss than previously recog›
nised, and we examined this issue in a community
sample of older adults from a population based, longi›
tudinal study.
Subjects, methods, and results
We collected data during five annual structured clinical
evaluations of subjects from a stratified random sample
of the population aged 65 years and older of East Bos›
ton, Massachusetts, a geographically defined commu›
nity. We measured weight and height, with participants
wearing light clothing, without shoes. Body mass index
(weight (kg)/height (m)2) was used to standardise
weight for height. Of the 467 clinical evaluation
subjects, 338 survived and underwent follow up assess›
ments and 280 (83%) had two or more weight
measurements. We diagnosed Alzheimer’s disease on
the basis of structured neurological examination,neuro›
psychological performance testing, brief psychiatric
evaluation, medical history, and review of drug
treatment. We used computerised Medicare hospital
discharge records to identify cancer, heart disease, and
congestive heart failure, using ICD›9›CM codes.2 We
used repeated measures and random effects regression
models to examine the relation between Alzheimer’s
disease and change in weight.
Figure 1 (top) presents a plot of the mean body
mass indices of the subjects with Alzheimer’s disease
and those without, at the five annual assessment
points. The figure overestimates the effects of the dis›
ease because people with the disease tend to be older.
After adjustment for both age and sex, the body mass
index in subjects without Alzheimer’s disease
decreased by an average of 0.14 a year, compared with
0.52 a year in similar subjects with probable Alzheim›
er’s disease, a difference of 0.38 (P < 0.01). A trend in
the data showed that severity of Alzheimer’s disease
did not modify weight loss: the body mass index
decreased by 0.59 a year in subjects with mild disease
and by 0.47 in those with advanced disease. The
reduction in body mass index associated with
Alzheimer’s disease was substantially greater than that
associated with heart disease (by 0.19, P = 0.05),
congestive heart failure (by 0.23, P = 0.07); and cancer
(by 0.14, P = 0.40). Figure 1 (bottom) illustrates the pre›
dicted trajectory of weight loss for an unaffected
woman of average age (78 years) and body mass index
(28.8) at baseline, compared with a similar woman
with Alzheimer’s disease.
Comment
Alzheimer’s disease is recognised as responsible for
weight loss both in clinical teaching and in several
studies of special groups,3 but the contribution of
specific conditions to weight loss has not been
examined carefully in population data. Several
features of this study strengthen confidence in its
results, including the longitudinal population based
design, adequate sample size, and uniform diagnostic
criteria for Alzheimer’s disease. Missing data may have
led to an underestimate of the relation between
Alzheimer’s disease and weight loss because the 187 of
467 participants with missing weights were generally
older, thinner, and more likely to have Alzheimer’s
disease.
The mechanisms linking Alzheimer’s disease and
weight loss are uncertain,3 but in this study many peo›
ple with Alzheimer’s disease had mild disease, and the
magnitude of weight loss in this group did not support
the idea that weight loss in Alzheimer’s disease is con›
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Fig 1 Top: Estimated weight loss (reduction in body mass index)
due to Alzheimer’s disease in stratified random community sample
of residents (unadjusted for age and sex). Bottom: Illustration of
predicted trajectory of weight loss for average 78 year old woman
with body mass index 28.8 at baseline (adjusted data, from a
random effects model)
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fined to those with severe disease. This differs from the
clinical perspective that weight loss occurs with
advanced disease and suggests that behavioural
problems—such as agitation and pacing—typically asso›
ciated with more advanced disease,4 do not fully
explain weight loss. Pathological changes in the
hypothalamus have been described in Alzheimer’s dis›
ease, and this pathology may affect centres regulating
food intake and metabolic processes.5
We thank the residents of East Boston and the staff of the
East Boston Neighborhood Health Center for their cooperation
and support. This project was presented in part at the annual
meeting of the Society for Epidemiologic Research, June 1995.
Funding: This work was supported in part by National Insti›
tute on Aging (grant AG›10161 and contracts N01›AG›12106
and N01›AG›02107) and the National Institute of Mental
Health (award K07›MH›00953).
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Prevalence of hepatitis C antibodies among healthcare
workers of two teaching hospitals. Who is at risk?
Keith R Neal, John Dornan, Will L Irving
Epidemiological evidence suggests that healthcare
workers are at an increased risk of hepatitis C
infection,1 and episodes of hepatitis C infection after
needlestick incidents2 and transmission of the virus in
hospitals in developed countries have also been
reported.3 Studies of prevalence in healthcare workers
so far published4 have neither supported nor
repudiated the increased risk suggested by the
epidemiological evidence. With increasing concern
about the risks of transmission of viruses such as hepa›
titis and HIV between patients and healthcare
workers,5 it is important that the real risk, if any, is
measured. We report the results of a study to measure
the prevalence of hepatitis C antibodies in healthcare
workers whose hepatitis B status was being assessed.
Patients, methods, and results
Blood samples taken from Nottingham hospital staff
for measuring hepatitis B surface antibody levels from
January 1994 to October 1995 were identified from the
virology computer and matched to data from the occu›
pational health database by record linkage using
surname, first name, date of birth, and date of blood
test. The database included main occupational group,
age, sex, and place and type of work. A unique study
number was attached to the combined data set and all
identifying features were removed. Microsoft Access
2.0 was used as the database and for record linkage and
spss for Windows for the statistical analyses.
A total of 1949 samples were retrieved and placed
into tubes with only the unique study number for iden›
tification. Hepatitis C antibody testing was performed
using a second generation ELISA (enzyme linked
immunoasorbent assay, UBI) according to the manu›
facturer’s instructions. All samples showing reactivity in
this assay were then tested using a third generation
ELISA (Ortho). Four samples positive in both ELISAs
were identified from 1949 samples, a rate of 2.05 per
1000 (95% confidence interval 0.55 to 5.2; table 1) The
number of positive results was too small for subgroup
analysis.
Comment
Our results show that the prevalence of hepatitis C
antibodies in healthcare workers is low. The use of
blood samples from staff who had already been identi›
fied as most at risk of infection by a blood borne virus
emphasises this low risk: many of the staff we included
in this study had been vaccinated as part of the original
targeted hepatitis B vaccine programme and had
blood taken for hepatitis B surface antibody titres
before their booster.
A case›control study of local blood donors showed
a rate of hepatitis C infection of 1 in 1350 (0.7 per
Table 1 Staff groups, by age and sex, of health care workers tested (number positive) for hepatitis C antibodies
Staff group
Age< 25 Age 25›44 Age > 45 All age groups Total (both
sexes)Women Men Women Men Women Men Women Men
Medical 33 36 77 (1) 175 11 31 121 (1) 242 363 (1)
Nursing 297 15 503 (1) 57 127 12 927 (1) 84 1011 (1)
Allied professions* 52 28 145 55 19 8 (1) 216 91 (1) 307 (1)
Others† 28 17 68 20 (1) 76 59 172 96 (1) 268 (1)
Total 410 96 793 (2) 307 (1) 233 110 (1) 1436 (2) 513 (2) 1949 (4)
* Includes ambulance crews, laboratory workers, physiotherapists, radiographers, and theatre staff.
† Includes domestics and porters.
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1000) and an increased risk in healthcare workers, with
a relative risk of 2.8.1 Our seroprevalence in high risk
healthcare workers was 2.05 per 1000, 2.9›fold higher
than in blood donors, a figure similar to that in the
case›control study. Nevertheless, although blood
donors are the largest group for whom prevalence data
exist, they are self selected individuals with a below
average risk for hepatitis C infection.
There are few studies of the prevalence of hepatitis
C infection in health care workers in countries with a
low prevalence of the infection, but one study in Lon›
don showed a prevalence consistent with ours—of 2.8
per 1000.4 A combination of this study and our results
gives a prevalence of 2.3 per 1000 (0.9 to 4.8 per 1000),
1 in 429 healthcare workers.
Because the study was anonymous we could not
identify other possible risk factors for the four people
with hepatitis C infection, such as a previous blood
transfusion or a history of injecting drug use. The real
rate of occupationally acquired hepatitis C infection
might be even lower. In conclusion, our results show
that the prevalence of hepatitis C infection among UK
healthcare workers is low and until risks of infection to
patients have been better documented routine testing
of healthcare workers performing exposure prone
activities is not warranted.
Funding: Wellcome Trust.
Conflict of interest: None.
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Severe persistent visual field constriction associated with
vigabatrin
T Eke, J F Talbot, M C Lawden
We report three cases of severe, symptomatic,
persistent constriction of the visual fields associated
with vigabatrin treatment.
Case reports
Case 1—A 22 year old woman with longstanding com›
plex partial epilepsy started taking vigabatrin 2000
mg/day in addition to carbamazepine 600 mg/day and
sodium valproate 1400 mg/day. Thirty seven months
later she complained of tunnel vision and was found to
have normal acuity but severely constricted visual fields
in both eyes (fig 1 (top)). Her optic discs were slightly
pale, and the peripheral retina seemed somewhat
atrophic. Magnetic resonance imaging showed left hip›
pocampal atrophy. Blood tests, including mitochon›
drial DNA screen and measurement of phytanic acid
and lysosomal enzyme concentrations, gave normal
results. Cone and rod electroretinography showed
normal a and b waves, but oscillatory potentials were
slightly subnormal. An electro›oculogram showed
abnormally low Arden indices (left 139%; right 167%).
Visual evoked responses were normal. Fluorescein
angiography showed spotty hyperfluorescence in
retinal pigment epithelium. Vigabatrin was discontin›
ued, but fields and symptoms showed no improvement
over the next 12 months.
Case 2—A 44 year old man with longstanding tem›
poral lobe epilepsy had vigabatrin 4000 mg/day added
to a regimen of phenytoin 400 mg/day and sodium
valproate 3000 mg/day. Twenty eight months later he
noticed constriction of his visual fields. Detailed assess›
ment showed normal acuity with appreciable contrac›
tion of the peripheral fields, particularly nasally (fig 1
(centre)). Ocular and neurological examinations gave
normal results, and magnetic resonance scanning
showed hippocampal asymmetry. Blood test results, as
for case 1, were normal. Vigabatrin treatment was dis›
continued 36 months later after temporal lobectomy.
Four years after presentation the optic discs were
slightly pale. Fluorescein fundus angiography showed
nothing unusual. Electro›oculography showed a low to
normal Arden index (185%). Electroretinography
showed normal latency and amplitudes for a and b
waves, but oscillatory potentials were not assessed.
Visual evoked responses were normal to both pattern
reversal and flash stimuli. Visual symptoms and fields
remained stable since presentation.
Case 3—A 46 year old woman with longstanding
complex partial epilepsy started taking vigabatrin 3500
mg/day in addition to carbamazepine 600 mg/day.
After 38 months she noticed that she was bumping into
objects, although her central vision remained normal.
Visual fields were concentrically constricted in both
eyes (fig 1 (bottom)), but funduscopy and fluorescein
angiography gave normal results. Electroretinography
showed reduced oscillatory potentials; electro›
diagnostic test results were otherwise normal. Magnetic
resonance imaging of the brain showed no abnormality.
Vigabatrin was stopped, but the fields failed to improve.
Comment
These three cases have the common feature of
symptomatic constriction of the visual field two to
three years after starting vigabatrin treatment. Though
visual complaints such as diplopia have occasionally
been reported with vigabatrin use,1 visual field impair›
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ment has rarely been noted. One reported case of uni›
lateral visual field constriction was ascribed to an
immune mediated anterior ischaemic optic
neuropathy.2 A literature search found brief details of
one other case of bilateral field constriction apparently
induced by vigabatrin.3 By January 1997 nine cases of
visual field defects had been reported to the
Committee on Safety of Medicines (Medicines Control
Agency, adverse drug reactions online information
tracking service), including our three cases. The manu›
facturers of vigabatrin had received 28 reports of visual
field abnormalities worldwide by January 1997 in an
estimated 140 000 patients treated (Hoechst Marion
Roussel, personal communication).
Vigabatrin causes microvacuolation in myelin
sheaths in the white matter of rats, mice, and dogs but
not in monkeys or humans.4 However, the low Arden
index and reduced oscillatory potentials in our cases
suggest that the outer retina rather than the optic nerve
is damaged. In albino but not pigmented rats vigabatrin
has a dose dependent effect on the outer retina,5
characterised histologically by disruption of the outer
nuclear layer. The significance of this finding to our own
observations is unclear. A prospective evaluation of
visual fields in asymptomatic patients taking vigabatrin
is in progress, and we have identified several other
abnormalities, which will be reported in due course.
Funding: None.
Conflict of interest: None.
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MISTAKES AVOIDED
On life and death certificates
From my corner of the cramped outpatient consulting room I could
see that the crowd in the waiting room was thinning out. The clinic
had been particularly hectic. One colleague was doing a caesarean
section. Another was on vacation in neighbouring Namibia. It was a
blessing that the nurses could manage most of the minor cases.
I pressed on with the next case—a patient with Parkinson’s disease
who was nearly frozen because the country had run out of the drug
he needed. Out of the corner of my eye I noticed one of the nurses
standing in the doorway cradling an emaciated and limp child in her
arms. I could tell that she wanted my attention, yet she was not in any
hurry. Nobody hurries here—except me when I first arrived. There was
a familiar looking form dangling from her hand—a death certificate. I
could almost certify deaths in my sleep. I thought of the bodies
stacked up in the mortuary, of aborted fetuses in plastic bags, and of
endless death certificates for unknown corpses.
I glanced at the nurse. “What’s up?”
In deference to the four other patients in the room waiting their
turn to see me she gave the familiar, almost imperceptible, Shona nod
and mouthed her reply: “Dead.”
Only wanting my signature, she gave the form a gentle wave. I
beckoned her over, took the form, and poised the pen to sign. I
hesitated, then looked at the child. Pale, shrivelled, lifeless—probably a
combination of malnutrition, tuberculosis, and AIDS. I returned to the
signing position with four pairs of eyes examining every move. The
advice of an acquaintance from long ago momentarily came to me:
“The only good doctor is a thorough doctor.”
I put the pen down. Reaching over the frozen man, I took the
child from the nurse. A brief but close inspection followed. Lifeless,
severely dehydrated, malnourished, but—wait—a flicker of movement
and, yes, the child was breathing.
Several weeks later a mother was ushered into the consulting
room carrying a fairly healthy looking little boy of around 2 years of
age. At first I could not tell why he was there. The writing on his card
looked familiar: “Child brought in ‘dead’ for certification. Resuscitated
with intravenous fluids and admitted for high calorie milk and high
protein diet.”
This has been my only fond memory of death certificates.
D Ashley R Watson is a fellow in infectious diseases at Harvard Medical
School, Boston, United States
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Fig 1 Goldmann visual fields 37 months after start of vigabatrin treatment (case 1, top),
28 months after start of vigabatrin treatment (case 2, centre), 38 months after start of
vigabatrin treatment (case 3, bottom)
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